(Total Views: 717)
Posted On: 04/30/2018 11:49:58 AM
Post# of 72433
This is a great indicator of how valuable an oral psoriasis drug with a strong safety profile can be. I also noticed that Allergan bought the dermatitis drug that failed in phase II as part of the deal. Given that we have several indications for B that are through Phase II successfully and will have a P phase II soon, this article provides comfort to me that Leo and Art are working on our best behalf in terms of value for the pipeline....al IMHO of course.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)